Global X Genomics & Biotechnology ETF
GNOM
54 hedge funds and large institutions have $121M invested in Global X Genomics & Biotechnology ETF in 2021 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 18 increasing their positions, 4 reducing their positions, and 5 closing their positions.
350% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 4
220% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 5
37% more capital invested
Capital invested by funds: $88.3M → $121M (+$33M)
20% more funds holding
Funds holding: 45 → 54 (+9)
2.23% more ownership
Funds ownership: 8.82% → 11.05% (+2.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Mirae Asset Global Investments
Seoul,
South Korea
|
+$21.3M |
| 2 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
+$8.98M |
| 3 |
CW
CreativeOne Wealth
Overland Park,
Kansas
|
+$5.01M |
| 4 |
SFS
Sowell Financial Services
North Little Rock,
Arkansas
|
+$1.98M |
| 5 |
MIG
McGuire Investment Group
Wakefield,
Rhode Island
|
+$1.78M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T
TRUADVICE
Sarasota,
Florida
|
-$3.65M |
| 2 |
FTUS
Flow Traders U.S.
New York
|
-$1.05M |
| 3 |
SPC
Sigma Planning Corp
Ann Arbor,
Michigan
|
-$455K |
| 4 |
PWM
PRW Wealth Management
Quincy,
Massachusetts
|
-$230K |
| 5 |
Barclays
London,
United Kingdom
|
-$100K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
JFA
51
JNBA Financial Advisors
Bloomington,
Minnesota
| $6K | – | – | – |
|
|
GWM
52
Geneos Wealth Management
Englewood,
Colorado
| $4K | +$4.68K | +50 | New |
|
53
Bank of Montreal
Toronto,
Ontario, Canada
| $3K | – | – | – |
|
|
PA
54
Parallel Advisors
San Francisco,
California
| $2K | – | – | – |
|
|
T
55
TRUADVICE
Sarasota,
Florida
| – | -$3.65M | -41,261 | Closed |
|
|
FTUS
56
Flow Traders U.S.
New York
| – | -$1.05M | -10,579 | Closed |
|
|
SPC
57
Sigma Planning Corp
Ann Arbor,
Michigan
| – | -$455K | -4,574 | Closed |
|
|
PWM
58
PRW Wealth Management
Quincy,
Massachusetts
| – | -$230K | -2,310 | Closed |
|
|
59
Barclays
London,
United Kingdom
| – | -$100K | -1,000 | Closed |
|
GNOM Hedge Fund Activity: Q3 2021 in Review
54 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Global X Genomics & Biotechnology ETF (GNOM) for Q3 2021, worth a combined $121M — up 37% from $88.3M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new GNOM positions and 5 closed out — a net gain of 11 holders — while 18 added to existing stakes and 4 trimmed.
The largest buyer was Mirae Asset Global Investments, adding an estimated $21.3M. The largest seller was TRUADVICE, exiting entirely with an estimated $3.65M sold.
- 54 institutional investors held Global X Genomics & Biotechnology ETF (GNOM) as of Q3 2021, up from 45 in Q2 2021.
- Funds reported $121M of Global X Genomics & Biotechnology ETF stock for Q3 2021, up 37% quarter-over-quarter.
- 16 funds opened new Global X Genomics & Biotechnology ETF positions in Q3 2021 and 5 closed out, a net change of +11 holders.
- The largest Global X Genomics & Biotechnology ETF buyer in Q3 2021 was Mirae Asset Global Investments, an estimated $21.3M added.
- The largest Global X Genomics & Biotechnology ETF seller in Q3 2021 was TRUADVICE, an estimated $3.65M sold.
Based on aggregated 13F filings for Q3 2021.